Charlotte S. Walmsley

Internal Medicine
330 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 23, 2025

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 05, 2024

Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions.

Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions.

Journal: Blood cells, molecules & diseases
Published: August 10, 2024

CRE24-035: Pembrolizumab-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Breast Cancer: A Case Report and Systematic Review of the Literature.

CRE24-035: Pembrolizumab-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Breast Cancer: A Case Report and Systematic Review of the Literature.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 05, 2024

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy.

Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy.

Journal: NPJ precision oncology
Published: June 20, 2022

An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression.

An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression.

Journal: Frontiers in oncology
Published: November 05, 2021

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.

Journal: Cancer discovery
Published: August 27, 2021

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.

Journal: Cancer discovery
Published: May 28, 2021

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer.

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer.

Journal: Nature communications
Published: February 25, 2020

The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.

The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 26, 2019

Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers.

Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers.

Journal: Cancer discovery
Published: March 29, 2019

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Journal: Cell chemical biology
Published: November 12, 2018
Showing 1-12 of 14

Last Updated: 09/26/2026